How immunotherapy is changing outcomes in triple-negative breast cancer

Triple-negative breast cancer has long been the subtype that keeps oncologists awake at night. Defined by the absence of oestrogen, progesterone and HER2 receptors, it represents roughly 10 to 15 percent of breast cancers diagnosed in Australia each year, and it disproportionately affects women under 50, those with BRCA1 gene alterations, and patients from some culturally and linguistically diverse backgrounds. The Australian Institute of Health and Welfare notes that breast cancer remains the most commonly diagnosed cancer in Australian women, so improvements in the hardest-to-treat forms carry significant weight for thousands of families.

For decades, chemotherapy was the workhorse of TNBC treatment. Endocrine therapy and HER2-targeted drugs, which transformed outcomes for other breast cancer subtypes, simply do not work because the molecular targets are missing. Immunotherapy changes that narrative by training the body's own immune system to recognise and attack tumour cells, offering a mechanism that does not depend on those traditional receptors.

The arrival of immune checkpoint inhibitors on the Pharmaceutical Benefits Scheme and their endorsement by the Therapeutic Goods Administration has shifted what is possible for Australian patients. Drugs such as pembrolizumab, which blocks the PD-1 pathway, can now be combined with chemotherapy before surgery for selected high-risk patients, a strategy known as neoadjuvant immunotherapy that is reshaping the standard of care.

The story is not yet finished. Real-world access, cost, rural reach and the management of immune-related side effects all shape how these breakthroughs land in practice, which is where Australian research networks and clinical registries are playing an increasingly important role.

The biological puzzle of triple-negative breast cancer

Triple-negative breast cancer is, in many ways, a label for what the tumour is not. Without the three receptors that guide most targeted therapies, clinicians have historically had to rely on broad-spectrum chemotherapy, often delivered at higher intensity and over longer periods. The cancer tends to grow faster, is more likely to spread to the brain and lungs, and carries a higher recurrence rate within the first five years after diagnosis.

One reason TNBC responds to immunotherapy is that it tends to have more tumour-infiltrating lymphocytes and a higher mutational burden than other subtypes. These features make the cancer look more "foreign" to the immune system, and therefore more susceptible to drugs that release the brakes on immune surveillance. Researchers in Brisbane and Melbourne have been at the forefront of mapping this biology, supported through collaborative funding such as the National Breast Cancer Foundation and state-based cancer councils.

Newer laboratory work is also uncovering subgroups within TNBC that may respond differently to different drugs. Subtypes such as the immunomodulatory, mesenchymal and basal-like profiles hint at a future where treatment is matched not just to the broad TNBC label but to the molecular signature inside each tumour.

From checkpoint inhibitors to clinical practice

The first wave of immunotherapy excitement in solid tumours came from melanoma and lung cancer. Breast cancer was initially seen as a poor candidate because the immune environment of most breast tumours was considered "cold." That view changed with trials such as IMpassion130 and KEYNOTE-355, which showed meaningful survival gains when checkpoint inhibitors were added to chemotherapy in metastatic TNBC.

The next leap came in the early-stage setting. The KEYNOTE-522 trial demonstrated that adding pembrolizumab to neoadjuvant chemotherapy roughly doubled the rate of pathological complete response, meaning no residual invasive cancer at surgery. This result, replicated in independent cohorts, helped pave the way for regulatory approval in early-stage disease.

In Australia, the Therapeutic Goods Administration listed pembrolizumab for high-risk early-stage TNBC in combination with chemotherapy, and the Pharmaceutical Benefits Scheme subsequently subsidised it. That combination of regulatory and reimbursement steps is critical because it means women receiving treatment through Queensland public hospitals, including Brisbane's Princess Alexandra and the Royal Brisbane and Women's Hospital, can access the drug without prohibitive out-of-pocket costs.

What biomarkers reveal about who benefits

Not every patient with TNBC responds to immunotherapy equally. Biomarker testing has become a routine part of the diagnostic work-up, helping oncologists predict who is most likely to benefit and who might face toxicity without meaningful gain. PD-L1 expression, measured using the combined positive score, remains the most widely used marker in metastatic disease.

In the early-stage setting, however, the story is more nuanced. KEYNOTE-522 enrolled patients regardless of PD-L1 status and still showed benefit, suggesting that biomarkers useful in advanced disease may not tell the whole story before surgery. Tumour-infiltrating lymphocytes, gene expression signatures and even gut microbiome patterns are under active investigation as more refined predictors.

Australian laboratories, including those affiliated with translational research nodes in Brisbane, are contributing to this biomarker discovery work. Each improvement in patient selection reduces the risk of offering an expensive, potentially toxic therapy to someone who will not benefit, while making sure those who will benefit are not missed.

Real-world evidence from Australian registries

Clinical trials tell us what works under tightly controlled conditions. Patient registries tell us what happens when the drug meets everyday practice, with all its messiness: older patients, comorbidities, missed appointments and varied supportive care. Patient registries are now central to how Australian clinicians refine their use of immunotherapy in TNBC.

Registries such as the Breast Cancer Registry Australia capture demographic details, tumour characteristics, treatment sequences and outcomes for thousands of women each year. They allow comparison of immunotherapy uptake between metropolitan Brisbane and regional centres, and flag rare toxicities that may only become visible when thousands of patients are followed.

These datasets also feed back into research priorities. When registry analyses reveal, for example, that older women are less likely to be offered immunotherapy, clinicians and policy makers can design targeted education and outreach to close that gap, ensuring the benefits seen in trials are shared more evenly across the population.

Equity, regional access and the patient journey

Approvals do not always translate into uniform care. Patients living in regional centres such as Toowoomba, Cairns or Rockhampton may need to travel to a tertiary cancer centre for immunotherapy infusion, monitoring and management of immune-related toxicities such as colitis, hepatitis or thyroid dysfunction. The cost of travel, time off work and caring responsibilities can quickly add up.

Telehealth follow-up, shared-care models between general practitioners and oncologists, and outreach clinics are helping bridge that gap. Cancer Council Queensland's transport-to-treatment services and accommodation subsidies around Brisbane's major hospitals also play a quiet but essential role in keeping regional patients on schedule with their treatment cycles.

There is also growing recognition that culturally safe care matters. For Aboriginal and Torres Strait Islander women, who experience different patterns of cancer outcomes, partnerships with community-controlled health organisations are helping ensure that new therapies are discussed in ways that respect language, family decision-making and connection to country.

AI tools helping surgical recovery

Most patients receiving neoadjuvant immunotherapy for TNBC go on to have surgery, often breast-conserving surgery or mastectomy with reconstruction. Predicting who will recover smoothly and who is at risk of complications such as wound infection has long been a clinical challenge.

New work based in Brisbane hospitals is using machine learning models to forecast post-operative infections before they occur, drawing on routine blood tests, medication lists and surgical details. Predicting post-surgical infections in this setting could help surgeons prioritise enhanced recovery pathways, prophylactic antibiotics or closer follow-up for those flagged as higher risk.

For a patient already navigating chemotherapy, immunotherapy and major surgery, having an early warning system that flags infection risk can mean fewer unexpected hospital admissions, shorter antibiotic courses and faster return to daily life. It is a small but meaningful way that data science is improving the lived experience of breast cancer treatment.

Looking ahead for patients and families

For someone newly diagnosed with TNBC in Brisbane, the Gold Coast or anywhere across Queensland, the conversation with their treating team will sound very different today than it did a decade ago. Combination immunotherapy plus chemotherapy is now a standard option for many patients with stage II and III disease, and clinical trials continue to test new combinations in the metastatic setting.

Patients should feel empowered to ask about biomarker testing, including PD-L1 expression and tumour-infiltrating lymphocytes, about clinical trial opportunities through groups such as ANZ Breast Cancer Trials, and about supportive care services that can ease the financial and emotional load of treatment.

Family members and carers also play a central role. Knowing the signs of immune-related side effects, helping with appointment reminders and advocating for timely reviews can all influence outcomes. Support groups run through Breast Cancer Network Australia connect patients across the country with others walking a similar path.

If you are a clinician, researcher or consumer representative working in breast cancer, consider connecting with the research themes and partnership opportunities available through Brisbane Diamantina Health Partners. Collaboration across hospitals, universities and community organisations is what turns laboratory discoveries into better days for patients and families touched by triple-negative breast cancer.